Alnylam, Isis Announce Notice of Allowance for RNAi-Related Patent Application | GenomeWeb

Alnylam Pharmaceuticals and Isis Pharmaceuticals said this week that the US Patent and Trademark Office has issued a notice of allowance for a US patent application covering chemically modified RNA-containing therapeutics.

The application, No. 20020165189, is entitled, "Oligoribonucleotides and Ribonucleases for Cleaving RNA," and specifically claims "oligoribonucleotides and oligoribonucleosides … [with] subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase," according to its abstract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.